

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4800438

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
ARNO THERAPEUTICS, INC.		12/15/2017
RECEIVING PARTY DATA		
Name:	CONTEXT BIOPHARMA INC.	
Street Address:	3025 MARKET STREET	
Internal Address:	SUITE 140	
City:	PHILADELPHIA	
State/Country:	PENNSYLVANIA	
Postal Code:	19104	
PROPERTY NUMBERS Total: 19		
Property Type	Number	
Application Number:	61777752	
Application Number:	14203814	
Application Number:	14661382	
PCT Number:	US2014023651	
Application Number:	61976872	
Application Number:	14681032	
PCT Number:	US2015024792	
Application Number:	62080868	
Application Number:	14942809	
Application Number:	62233166	
Application Number:	15274555	
PCT Number:	US2016053435	
Application Number:	62267540	
Application Number:	15378004	
PCT Number:	US2016066420	
Application Number:	62310944	
Application Number:	15464085	
PCT Number:	US2017023256	
PCT Number:	US2015060940	

PATENT

CORRESPONDENCE DATA**Fax Number:** (202)318-7707

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (301)337-7523**Email:** patents@potomacclaw.com, slee@potomacclaw.com**Correspondent Name:** POTOMAC LAW GROUP, PLLC**Address Line 1:** 1300 PENNSYLVANIA AVENUE, NW**Address Line 2:** SUITE 700**Address Line 4:** WASHINGTON, D.C. 20004

ATTORNEY DOCKET NUMBER:	1974-0015PV01
NAME OF SUBMITTER:	SE JIN LEE
SIGNATURE:	/Se Jin Lee/
DATE SIGNED:	01/30/2018

Total Attachments: 9

source=Assignment_Arno to Context_executed#page1.tif

source=Assignment_Arno to Context_executed#page2.tif

source=Assignment_Arno to Context_executed#page3.tif

source=Assignment_Arno to Context_executed#page4.tif

source=Assignment_Arno to Context_executed#page5.tif

source=Assignment_Arno to Context_executed#page6.tif

source=Assignment_Arno to Context_executed#page7.tif

source=Assignment_Arno to Context_executed#page8.tif

source=Assignment_Arno to Context_executed#page9.tif

PATENT RIGHTS ASSIGNMENT

This Patent Rights Assignment (this "Assignment") is made effective this 15th day of December, 2017, by and between ARNO THERAPEUTICS, INC., a Delaware corporation ("Assignor") and CONTEXT BIOPHARMA INC., a Delaware corporation ("Assignee").

WHEREAS, Assignor possesses certain rights in and to the patents and patent applications (and patents issuing on such applications) including, but not limited to as, set forth on Exhibit A attached hereto and incorporated herein by reference (collectively, the "Patent Rights") and the invention(s) described and/or claimed in the Patent Rights (the "Inventions"); and

WHEREAS, Assignor and Assignee are parties to that certain Asset Purchase Agreement, dated as of December 15, 2017 (the "Purchase Agreement"), pursuant to which Assignor transferred, sold and conveyed to Assignee certain of the assets of Assignor, including the Inventions and Patent Rights; and

WHEREAS, Assignor now wishes to assign the Inventions and Patent Rights to Assignee, and Assignee desires to acquire the Inventions and Patent Rights from Assignor.

NOW, THEREFORE, in consideration of the premises set forth above and in the Purchase Agreement and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged:

Assignor does hereby sell, assign, convey and transfer unto Assignee and its successors, assigns, and legal representatives, Assignor's entire right, title and interest in and throughout the world in and to the Inventions, together with Assignor's entire right, title and interest in and to the Patent Rights and such other patents as may issue thereon or claim priority under United States law or international convention, including but not limited to non-provisionals, continuations, divisionals, reissues, reexaminations, reviews, extensions, and substitutions of patents and patent applications within the Patent Rights or such other patents, and any right, title and interest Assignor may have in applications to which the Patent Rights claim priority; the Inventions and the Patent Rights to be held and enjoyed by Assignee for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said patents may be granted as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made; and Assignor hereby conveys all of its rights arising under or pursuant to any and all United States laws and international agreements, treaties or laws relating to the protection of industrial property including but not limited to the right to bring any cause(s) of action and damages for past, present and future infringement or other violation thereof. Assignor hereby acknowledges that this assignment, being of Assignor's entire right, title and interest in and to the Inventions and the Patent Rights carries with it the right in Assignee to apply for and obtain from competent authorities in all countries of the world any and all patents by attorneys and agents of Assignee's selection and the right to procure the grant of all patents to Assignee in its own name as assignee of Assignor's entire right, title and interest therein.

Assignor does hereby authorize the Director of the United States Patent & Trademark Office, and the empowered officials of all other governments whose duty it is to record patents, applications and title thereto, to record the Patent Rights and title thereto as the property of Assignee, its successors, assigns, or legal representatives in accordance with the terms of this instrument.


Assignor does hereby further authorize and request the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue such Patent Rights or patents as shall be granted upon the Patent Rights, or applications based thereon, to Assignee, its successors, assigns, or legal representatives.

Assignors, for themselves and their successors and assigns, agree, without further consideration, from time to time after the execution of this Assignment, to (i) execute and deliver further instruments of transfer, assumption and assignment and take such other actions as the Assignee may reasonably require to transfer, assign to and vest in Assignee the Inventions and the Patent Rights; (ii) cooperate with and provide assistance to Assignee in transferring possession of the Inventions and the Patent Rights to Assignee; and (iii) do, execute, acknowledge and deliver or cause to be done, executed, acknowledged and delivered all and every further act, deed, conveyance, transfer and assurance necessary to assure their compliance with the terms, provisions, purposes and intents of this Assignment and the effectiveness of the rights, benefits and remedies provided for hereby.

Assignee and Assignor also agree that multiple copies of this Assignment may be executed, each of which shall be deemed an original, and each of which shall be valid and binding upon Assignee and Assignor.

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be executed by their duly authorized representatives as of the date first written above.

ASSIGNOR: ARNO THERAPEUTICS, INC.,
Name: Alexander Zukiwski
Signature: 
Title: Chief Executive Officer

ASSIGNEE: CONTEXT BIOPHARMA INC.
Name: Martin Lehr
Signature: _____
Title: Chief Executive Officer

IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be executed by their duly authorized representatives as of the date first written above.

ASSIGNOR: ARNO THERAPEUTICS, INC.,
Name: _____
Signature: _____
Title: _____

ASSIGNEE: CONTEXT BIOPHARMA INC.
Name: Martin Lehr
Signature: *Martin Lehr*
Title: Chief Executive Officer

Exhibit A

Application No.	Filing Date	Country or Jurisdiction	Title
61/777,752	12-Mar-2013	U.S.	Onapristone Polymorphic Forms And Methods Of Use
14/203,814	11-Mar-2014	U.S.	Onapristone Polymorphic Forms And Methods Of Use
14/661,382	18-Mar-2015	U.S.	Onapristone Polymorphic Forms And Methods Of Use
PCT/US14/23651	11-Mar-2014	PCT	Onapristone Polymorphic Forms And Methods Of Use
2014248928	11-Mar-2014	Australia	Onapristone Polymorphic Forms And Methods Of Use
2904116	11-Mar-2014	Canada	Onapristone Polymorphic Forms And Methods Of Use
2014800143291	11-Mar-2014	China	Onapristone Polymorphic Forms And Methods Of Use
147259303	11-Mar-2014	EPO	Onapristone Polymorphic Forms And Methods Of Use
161063905	11-Mar-2014	Hong Kong	Onapristone Polymorphic Forms And Methods Of Use
9086DELNP2015	11-Mar-2014	India	Onapristone Polymorphic Forms And Methods Of Use
2016501305	11-Mar-2014	Japan	Onapristone Polymorphic Forms And Methods Of Use

Exhibit A to Patent Rights Assignment

Application No.	Filing Date	Country or Jurisdiction	Title
1020157027542	11-Mar-2014	Korea	Onapristone Polymorphic Forms And Methods Of Use
MXA2015012142	11-Mar-2014	Mexico	Onapristone Polymorphic Forms And Methods Of Use
2015137837	11-Mar-2014	Russia	Onapristone Polymorphic Forms And Methods Of Use
61/976872	08-Apr-2014	U.S.	Systems And Methods For Identifying Progesterone Receptor Subtypes
14/681032	07-Apr-2015	U.S.	Systems And Methods For Identifying Progesterone Receptor Subtypes
PCT/US15/24792	07-Apr-2015	PCT	Systems And Methods For Identifying Progesterone Receptor Subtypes
2015243969	07-Apr-2015	Australia	Systems And Methods For Identifying Progesterone Receptor Subtypes
2939241	07-Apr-2015	Canada	Systems And Methods For Identifying Progesterone Receptor Subtypes
201580012684X	07-Apr-2015	China	Systems And Methods For Identifying Progesterone Receptor Subtypes
157762519	07-Apr-2015	EPO	Systems And Methods For Identifying Progesterone Receptor Subtypes

Exhibit A to Patent Rights Assignment

#46600887 v1
156289791 v1

PATENT
REEL: 044769 FRAME: 0627

Application No.	Filing Date	Country or Jurisdiction	Title
201617037344	07-Apr-2015	India	Systems And Methods For Identifying Progesterone Receptor Subtypes
2016552967	07-Apr-2015	Japan	Systems And Methods For Identifying Progesterone Receptor Subtypes
1020167024180	07-Apr-2015	Korea	Systems And Methods For Identifying Progesterone Receptor Subtypes
MXA2016010499	07-Apr-2015	Mexico	Systems And Methods For Identifying Progesterone Receptor Subtypes
2016133175	07-Apr-2015	Russia	Systems And Methods For Identifying Progesterone Receptor Subtypes
62/080868	17-Nov-2014	U.S.	Onapristone Pharmacokinetics
14/942809	16-Nov-2015	U.S.	Onapristone Extended-Release Compositions And Methods
PCT/US15/60940	16-Nov-2015	PCT	Onapristone Extended-Release Compositions And Methods
2015350241	16-Nov-2015	Australia	Onapristone Extended-Release Compositions And Methods
2966753	16-Nov-2015	Canada	Onapristone Extended-Release Compositions And Methods
201580062192.1	16-Nov-2015	China	Onapristone Extended-Release Compositions And Methods

Exhibit A to Patent Rights Assignment

#46600887 v1
156289791 v1

PATENT
REEL: 044769 FRAME: 0628

Application No.	Filing Date	Country or Jurisdiction	Title
15861014	16-Nov-2015	EPO	Onapristone Extended-Release Compositions And Methods
2017-520520	16-Nov-2015	Japan	Onapristone Extended-Release Compositions And Methods
10-2017-7012909	16-Nov-2015	Korea	Onapristone Extended-Release Compositions And Methods
MX/A/2017/005163	16-Nov-2015	Mexico	Onapristone Extended-Release Compositions And Methods
2017112748	16-Nov-2015	Russia	Onapristone Extended-Release Compositions And Methods
62/233166	25-Sep-2015	U.S.	Methods Of Making Onapristone Intermediates
15/274555	23-Sep-2016	U.S.	Methods Of Making Onapristone Intermediates
PCT/US16/53435	23-Sep-2016	PCT	Methods Of Making Onapristone Intermediates
62/267540	15-Dec-2015	U.S.	Amorphous Onapristone Compositions And Methods Of Making The Same
15/378004	13-Dec-2016	U.S.	Amorphous Onapristone Compositions And Methods Of Making The Same
PCT/US16/66420	13-Dec-2016	PCT	Amorphous Onapristone Compositions And Methods Of Making The Same

Exhibit A to Patent Rights Assignment

#46600887 v1
156289791 v1

PATENT
REEL: 044769 FRAME: 0629

Application No.	Filing Date	Country or Jurisdiction	Title
62/310944	21-Mar-2016	U.S.	Onapristone Metabolite Compositions And Methods
15/464085	20-Mar-2017	U.S.	Onapristone Metabolite Compositions And Methods
PCT/US17/23256	20-Mar-2017	PCT	Onapristone Metabolite Compositions And Methods
62/428401	30-Nov-2016	U.S.	Methods For Onapristone Synthesis Dehydration And Deprotection

Exhibit A to Patent Rights Assignment

#46600887 v1
156289791 v1

RECORDED: 01/30/2018

PATENT
REEL: 044769 FRAME: 0630